Fuji Pharma Co., Ltd.

As of March 31, 2026, Fuji Pharma Co., Ltd. carries a market capitalization of 342.17M, placing it among publicly traded companies globally. Its enterprise value stands at 444.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fuji Pharma Co., Ltd.'s next confirmed earnings release is scheduled for November 10, 2026.

As of March 31, 2026, Fuji Pharma Co., Ltd. has 26.12M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Fuji Pharma Co., Ltd. maintains a current ratio of 1.68, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Fuji Pharma Co., Ltd.'s stock has gained approximately 16.02% over the past 52 weeks. The 50-day moving average sits at 10.01, while the 200-day moving average is 11.18.

As of March 31, 2026, Fuji Pharma Co., Ltd. holds 59.35M in cash and equivalents against 161.46M in total debt, resulting in a net debt position of 78.04M. Total book value stands at 279.98M, with working capital of 120.05M providing operational flexibility.

Fuji Pharma Co., Ltd.'s most recent stock split took place on June 27, 2018 with a 1:2 split ratio.